These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6480147)

  • 1. Biodistribution of 6-[211At]astato-2-methyl-1,4-naphthoquinol bis(diphosphate salt) and 211At- in mice with a transplanted rectal adenocarcinoma.
    Brown I; Carpenter RN; Mitchell JS
    Int J Appl Radiat Isot; 1984 Sep; 35(9):843-7. PubMed ID: 6480147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. alpha-Particle track autoradiography for localization of a 211At-astatinated drug.
    Mitchell JS; Brown I; Carpenter RN
    Experientia; 1983 Mar; 39(3):337-9. PubMed ID: 6825808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of a [211At]-astatinated endoradiotherapeutic drug: Part II. Therapeutic results for transplanted adenocarcinoma of the rectum in mice and associated studies.
    Brown I; Mitchell JS
    Int J Radiat Oncol Biol Phys; 1994 Apr; 29(1):115-24. PubMed ID: 8175418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-particle track autoradiographic study of the distribution of a [211At]-astatinated drug in normal tissues of the mouse.
    Mitchell JS; Brown I; Carpenter RN
    Experientia; 1985 Jul; 41(7):925-8. PubMed ID: 4007129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of a [211AT]-astatinated endoradiotherapeutic drug: part IV--late radiation effects.
    Brown I; Mitchell JS
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1177-83. PubMed ID: 9539575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-211 At-astato-2-methyl-1,4-naphthoquinol bis (disodium phosphate): a novel alpha-emitting potential anti-tumour drug.
    Brown I
    Int J Appl Radiat Isot; 1982 Jan; 33(1):75-6. PubMed ID: 7061164
    [No Abstract]   [Full Text] [Related]  

  • 7. The development of A [211At]-astatinated endoradiotherapeutic drug: Part I. Localization by alpha-particle autoradiography in a murine tumor model.
    Brown I; Carpenter RN; Mitchell JS
    Int J Radiat Oncol Biol Phys; 1992; 23(3):563-72. PubMed ID: 1612957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioactive derivatives of 2-methyl-1, 4-naphthoquinol bis (diphosphate salt) as anti-cancer drugs with high LET radiations.
    Mitchell JS; Brown I; Carpenter RN
    Prog Clin Biol Res; 1984; 166():327-35. PubMed ID: 6504938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells.
    Larsen RH; Vaidyanathan G; Zalutsky MR
    Int J Radiat Biol; 1997 Jul; 72(1):79-90. PubMed ID: 9246197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide.
    Garg PK; John CS; Zalutsky MR
    Nucl Med Biol; 1995 May; 22(4):467-73. PubMed ID: 7550023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
    Vaidyanathan G; Zhao XG; Larsen RH; Zalutsky MR
    Br J Cancer; 1997; 76(2):226-33. PubMed ID: 9231923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy.
    Foulon CF; Alston KL; Zalutsky MR
    Nucl Med Biol; 1998 Feb; 25(2):81-8. PubMed ID: 9468020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.
    Larsen RH; Murud KM; Akabani G; Hoff P; Bruland OS; Zalutsky MR
    J Nucl Med; 1999 Jul; 40(7):1197-203. PubMed ID: 10405142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.
    Reist CJ; Foulon CF; Alston K; Bigner DD; Zalutsky MR
    Nucl Med Biol; 1999 May; 26(4):405-11. PubMed ID: 10382844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model.
    Vaidyanathan G; Friedman HS; Keir ST; Zalutsky MR
    Nucl Med Biol; 1996 Aug; 23(6):851-6. PubMed ID: 8940730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac.
    Yordanov AT; Garmestani K; Zhang M; Zhang Z; Yao Z; Phillips KE; Herring B; Horak E; Beitzel MP; Schwarz UP; Gansow OA; Plascjak PS; Eckelman WC; Waldmann TA; Brechbiel MW
    Nucl Med Biol; 2001 Oct; 28(7):845-56. PubMed ID: 11578907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.
    McLendon RE; Archer GE; Larsen RH; Akabani G; Bigner DD; Zalutsky MR
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):491-9. PubMed ID: 10487576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds.
    Larsen RH; Slade S; Zalutsky MR
    Nucl Med Biol; 1998 May; 25(4):351-7. PubMed ID: 9639296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At.
    Vaidyanathan G; Affleck DJ; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2003 May; 30(4):351-9. PubMed ID: 12767391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.
    Vaidyanathan G; Zalutsky MR
    Bioconjug Chem; 1992; 3(6):499-503. PubMed ID: 1463779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.